The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 428-440

  Smith, Nicola F ^a,b   Raynaud, Florence I ^a   Workman, Paul ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; BOHEMINE; CCT 018159; CCT 066950; CCT 066952; CCT 066963; CCT 066965; CYCLIN DEPENDENT KINASE INHIBITOR; ETHAMBUTOL; HEAT SHOCK PROTEIN 90 INHIBITOR; INDINAVIR; INDINAVIR DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; NSC 255110; NSC 682300; NSC 683661; NSC 683663; OLOMOUCINE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PURVALANOL A; PYRROLIDINE DERIVATIVE; RESORCINOL DERIVATIVE; ROSCOVITINE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 33847405771     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0324     Document Type: Review

References (85)

1. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol 2003;52 Suppl 1:45-56.
2. Workman P. Genomics and the second golden era of cancer drug development. Mol Biosyst 2005;1:17-26.
3. Workman P. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harb Symp Quant Biol 2005;70:1-18.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
5. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
6. PhRMA Pharmaceutical Industry Profile 2003. Washington (DC): PhRMA; 2003.
7. Aherne GW, Garrett M, McDonald E, Workman P. Mechanism-based high throughput screening for novel anticancer drug discovery. In: B.C. Baguley, editor. Anti-cancer drug design. San Diego (CA): Academic Press; 2002. p. 249-67.
8. Aheme GW, McDonald E, Workman P. Finding the needle in the haystack: why high-throughput screening is good for your health. Breast Cancer Res 2002;4:148-54.
9. Clarke PA, te Poele R, Workman P. Gene expression microarray technologies in the development of new therapeutic agents. Eur J Cancer 2004;40:2560-91.
10. Schuster D, Laggner C, Langer T. Why drugs fail-a study on side effects in new chemical entities. Curr Pharm Des 2005;11:3545-59.
11. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7:165-82.
12. Watt AP, Morrison II, Evans DC. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discov Today 2000;5: 17-24.
13. Collins I, Workman P. Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets. Curr Sig Trans Ther 2006;1:13-23.
14. Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997;2:436-44.
15. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988;25:387-96.
16. Roberts SA. Drug metabolism and pharmacokinetics in drug discovery. Curr Opin Drug Discov Devel 2003;6:66-80.
17. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46:3-26.
18. Beresford AP, Segall M, Tarbit MH. In silico prediction of ADME properties: are we making progress? Curr Opin Drug Discov Devel 2004;7: 36-42.
19. Subramanian K. truPK-human pharmacokinetic models for quantitative ADME prediction. Expert Opin Drug Metab Toxicol 2005;1: 555-64.
20. Ungell A-LB. Caco-2 replace or refine. Drug Discov Today Tech 2004; 1:423-30.
21. Kansy M, Avdeef A, Fischer H. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug Discov Today Tech 2004;1:349-55.
22. Riley RJ, Grime K. Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. Drug Discov Today Tech 2004;1:365-72.
23. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP183 in governing drug elimination. Expert Opin Drug Metab Toxicol 2006;1:429-45.
24. Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004;32:1311-6.
25. Masereeuw R, Russel F. Screening for the role of transporters in hepatic and renal drug handling. Drug Discov Today Tech 2004;1: 357-64.
26. Cox KA, White RE, Korfmacher WA. Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches. Comb Chem High Throughput Screen 2002;5:29-37.
27. Lee MS, Kerns EH. LC/MS applications in drug development. Mass Spectrom Rev 1999;18:187-279.
28. Brewer E, Henion J. Atmospheric pressure ionization LC/MS/MS techniques for drug disposition studies. J Pharm Sci 1998;87:395-402.
29. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom Rev 2003;22:195-214.
30. Korfmacher WA, Cox KA, Bryant MS, et al. HPLC-API/MS/MS: a powerful tool for integrating metabolism into the drug discovery process. Drug Discov Today 1997;2:532-7.
31. Atherton JP, Van Noord TJ, Kuo BS. Sample pooling to enhance throughput of brain penetration study. J Pharm Biomed Anal 1999;20: 39-47.
32. Kuo BS, Van Noord T, Fang MR, Wright DS. Sample pooling to expedite bioanalysis and pharmacokinetic research. J Pharm Biomed Anal 1998;16:837-46.
33. Singh RP, Singh SK, Gupta RC. A high throughput approach for simultaneous estimation of multiple synthetic trioxane derivatives using sample pooling for pharmacokinetic studies. J Pharm Biomed Anal 2005; 37:127-33.
34. Cox KA, Dunn-Meynell K, Korfmacher WA, et al. Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discov Today 1999;4:232-7.
35. Hop CE, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 1998;87:901-3.
36. Korfmacher WA, Cox KA, Ng KJ, et al. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/ atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun Mass Spectrom 2001;15:335-40.
37. Berman J, Halm K, Adkison K, Shaffer J. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using APILC/MS/MS analysis for increased throughput. J Med Chem 1997;40:827-9.
38. Bayliss MK, Frick LW. High-throughput pharmacokinetics: cassette dosing. Curr Opin Drug Discov Devel 1999;2:20-5.
39. Frick LW, Adkison KK, Wells-Knecht KJ, Woollard P, Higton DM. Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharm Sci Technol Today 1998;1:12-8.
40. Public Health Service Policy on Humane Care and Use of Laboratory Animals. 2002.
41. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
42. White RE, Manitpisitkul P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos 2001;29:957-66.
43. Ackermann BL. Results from a bench marking survey on cassette dosing practices in the pharmaceutical industry. J Am Soc Mass Spectrom 2004;15:1374-7.
44. Manitpisitkul P, White RE. Whatever happened to cassette-dosing pharmacokinetics? Drug Discov Today 2004;9:652-8.
45. Tamvakopoulos CS, Colwell LF, Barakat K, et al. Determination of brain and plasma drug concentrations by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2000;14:1729-35.
46. Zhang MY, Kerns E, McConnell O, et al. Brain and plasma exposure profiling in early drug discovery using cassette administration and fast liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2004;34:359-68.
47. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 2004;3:353-62.
48. Smith NF, Hayes A, James K, et al. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol Cancer Ther 2006;5:1628-37.
49. Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. Cancer Chemother Pharmacol 2004;54: 475-86.
50. Nutley BP, Raynaud FI, Wilson SC, et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005;4:125-39.
51. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine, and CYC202. Clin Cancer Res 2005;11:4875-87.
52. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152-61.
53. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3:377-83.
54. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
55. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998; 58:2385-96.
56. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
57. Dymock BW, Drysdale MJ, McDonald E, Workman P. Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert Opin Ther Patents 2004;14:837-47.
58. McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1193-203.
59. Cheung KM, Matthews TP, James K, et al. The identification, synthesis, protein crystal structure, and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-43.
60. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004;327:176-83.
61. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 16:303-9.
62. Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci 1993;83:761-3.
63. Dymock BW, Barril X, Brough PA, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 2005;48:4212-5.
64. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002;38:2189-93.
65. Workman P. How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
66. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5: 741-54.
67. McLoughlin DA, Olah TV, Gilbert JD. A direct technique for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry interfaced to a Prospekt solid-phase extraction system. J Pharm Biomed Anal 1997;15:1893-901.
68. Olah TV, McLoughlin DA, Gilbert JD. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom 1997;11:17-23.
69. Allen MC, Shah TS, Day WW. Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and application. Pharm Res 1998;15:93-7.
70. Shaffer JE, Adkison KK, Halm K, Hedeen K, Berman J. Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. J Pharm Sci 1999;88: 313-8.
71. Gao VC, Luo WC, Ye Q, Thoolen M. Column switching in high-performance liquid chromatography with tandem mass spectrometric detection for high-throughput preclinical pharmacokinetic studies. J Chromatogr A 1998;828:141-8.
72. Rano TA, Cheng Y, Huening TT, et al. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library. Bioorg Med Chem Lett 2000;10:1527-30.
73. Wu JT, Zeng H, Qian M, Brogdon BL, Unger SE, Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. Anal Chem 2000;72:61-7.
74. Rajanikanth M, Gupta RC. LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing 'N-in-One' dosing. J Pharm Biomed Anal 2001;26:519-30.
75. Zeng H, Wu JT, Unger SE. The investigation and the use of high flow column-switching LC/MS/MS as a high-throughput approach for direct plasma sample analysis of single and multiple components in pharmacokinetic studies. J Pharm Biomed Anal 2002;27:967-82.
76. Hasegawa K, Shindoh H, Shiratori Y, et al. Cassette dosing approach and quantitative structure-pharmacokinetic relationship study of antifungal N-myristoyltransferase inhibitors. J Chem Inf Comput Sci 2002;42:968-75.
77. Macdonald SJ, Dowle MD, Harrison LA, et al. Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). J Med Chem 2002;45: 3878-90.
78. Andrews DM, Barnes MC, Dowle MD, et al. Pyrrolidine-5,5-translactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease. Org Lett 2003;5:4631-4.
79. Ohkawa T, Ishida Y, Kanaoka E, et al. A new generic column switching system for quantitation in cassette dosing using LC/MS/MS. J Pharm Biomed Anal 2003;31:1089-99.
80. Mallis LM, Sarkahian AB, Harris HA, Zhang MY, McConnell OJ. Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:71-86.
81. Tong XS, Wang J, Zheng S, Pivnichny JV. High-throughput pharmacokinetics screen of VLA-4 antagonists by LC/MS/MS coupled with automated solid-phase extraction sample preparation. J Pharm Biomed Anal 2004;35:867-77.
82. Sadagopan N, Pabst B, Cohen L. Evaluation of online extraction/mass spectrometry for in vivo cassette analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2005;820:59-67.
83. Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M. Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J Pharm Biomed Anal 2005;37:793-9.
84. Janser P, Neumann U, Miltz W, Feifel R, Buhl T. A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett 2006;16:2632-6.
85. Sarker D, Workman P. Pharmacodynamic biomarkers for Molecular Cancer Therapeutics. Adv Cancer Res 2006;96:213-68.